A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”

Matthias Augustin, April W. Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres

Open source

DOI
10.1007/s13555-026-01798-8
Published
2026-06-26
Container
Dermatology and Therapy
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s13555-026-01798-8,
  title = {A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”},
  author = {Matthias Augustin and April W. Armstrong and Naiem T. Issa and Anne Sohrt Petersen and Rie von Eyben and Teodora Festini and Tiago Torres},
  year = {2026},
  journal = {Dermatology and Therapy},
  doi = {10.1007/s13555-026-01798-8},
  url = {https://doi.org/10.1007/s13555-026-01798-8}
}

RIS

TY  - JOUR
TI  - A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”
AU  - Matthias Augustin
AU  - April W. Armstrong
AU  - Naiem T. Issa
AU  - Anne Sohrt Petersen
AU  - Rie von Eyben
AU  - Teodora Festini
AU  - Tiago Torres
PY  - 2026
JO  - Dermatology and Therapy
DO  - 10.1007/s13555-026-01798-8
UR  - https://doi.org/10.1007/s13555-026-01798-8
ER  - 

APA

Augustin, M., Armstrong, A. W., Issa, N. T., Petersen, A. S., Eyben, R. V., Festini, T., & Torres, T. (2026). A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”. Dermatology and Therapy. https://doi.org/10.1007/s13555-026-01798-8

Source records